English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In five clinical trials AM3, a polysaccharide/protein biological response modifier, was given (3 g/day; two capsules, tid) to 79 breast cancer patientsundergoing adjuvant radio- and/or chemotherapies. When compared with 68 control patients, AM3provoked significant decreases in the incidence of bone-marrow hypoplasia (20.5% versus 61.1%). Thismarrow effect was also manifested in peripheral blood by higher levels of white blood cells, mononuclearcells and platelets in the AM3 treated group. The incidence of thrombocytopenia in patients receivingcombined radio-chemotherapy only was 70% compared with 6% observed in patients also receiving AM3treatment. Besides these hematological effects, AM3 palliated subclinical hepatic toxicity due to combinedradio-chemotherapy. Finally, studies on acute-phase reactants, such as C-reactive protein, IgA. and factorsB, C'3, and C'5 of the complement system, suggest that a modulation of hepatic inflammatory responsesby AM3 appears to be essential for clinical effects described

canadian journal of infectious diseases

AM3, an Oral BRM: Protective Agent against Iatrogenic Bone-Marrow and Liver Damage in Breast Cancer Patients under Conventional Adjuvant Radiochemotherapy